×
About 11,635 results

FDA Rejects More China Drugs; Clue to Uterine Ca Disparity; Cancer-Vax Controversy
https://www.medpagetoday.com/hematologyoncology/othercancers/98587

May 6th, 2022 - China-based Hutchmed announced receipt of a complete response letter from the FDA, stating that the agency cannot approve the tyrosine kinase inhibitor surufatinib for advanced neuroendocrine tumors without support from a multiregional clinical trial. Coherus and Junshi Biosciences also received a complete response letter for PD-1 inhibitor toripalimab as a treatment for advanced or metastatic ...

Young Cancer Survivors Face Higher Risk of Death From Second Malignancies
https://www.medpagetoday.com/hematologyoncology/othercancers/98528

May 4th, 2022 - Adolescent and young adult (AYA) cancer survivors have a significantly increased risk for developing a new cancer and dying from that cancer, according to a population-based study. These younger cancer survivors had a 25% higher risk for cancer incidence, and an 84% higher risk for cancer death, compared with the general population, reported Hyuna Sung, PhD, of the American Cancer Society, and ...

Corticosteroids Linked to Pain Events in Patients With Sickle Cell Disease
https://www.medpagetoday.com/hematologyoncology/hematology/98514

May 2nd, 2022 - Patients with sickle cell disease (SCD) have an increased risk of vaso-occlusive episodes (VOE) after exposure to corticosteroids, according to a French population-based study. Those taking systemic corticosteroids were nearly four times more likely to be hospitalized for a VOE a month after exposure (adjusted odds ratio [aOR] 3.8, 95% CI 2.4-5.6), reported Ondine Walter, MD, of Toulouse Univer...

Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC
https://www.medpagetoday.com/hematologyoncology/lungcancer/98513

May 2nd, 2022 - Patients with unresectable stage III non-small cell lung cancer (NSCLC) had a higher response rate and better progression-free survival when novel targeted agents were added to treatment with durvalumab (Imfinzi), a phase II randomized trial showed. Objective response rate improved from 17.9% with durvalumab alone to 30.0% with the addition of the anti-CD73 agent oleclumab and to 35.5% with dur...

End of the Line for a Failed Prostate Cancer Drug
https://www.medpagetoday.com/hematologyoncology/prostatecancer/98488

Apr 29th, 2022 - The androgen synthesis inhibitor orteronel failed to improve survival in metastatic hormone-sensitive prostate cancer (mHSPC) despite a twofold improvement in progression-free survival (PFS) versus standard androgen-deprivation therapy (ADT), a large randomized trial showed. Patients randomized to ADT plus orteronel had a median overall survival (OS) of 81 months compared with 70.2 months with ...

Extra COVID Jab for Cancer Patients; VA to Cover More Cancers; Cancer's Origin Story
https://www.medpagetoday.com/hematologyoncology/othercancers/98467

Apr 29th, 2022 - The National Comprehensive Cancer Network endorsed a second COVID mRNA booster for immunocompromised individuals, bringing the total to five jabs, as three is considered standard for someone who is immunocompromised. In a first-quarter earnings statement, Roche announced that a phase II trial of the selective estrogen receptor degrader giredestrant did not meet the primary endpoint of progressi...

Some Reassurance on Neurologic Effects of Checkpoint Inhibitors
https://www.medpagetoday.com/hematologyoncology/othercancers/98373

Apr 22nd, 2022 - Cancer patients treated with immune checkpoint inhibitors (ICIs) had different tradeoffs in neurologic side effects compared with users of other medications, according to a meta-analysis of over three dozen randomized trials. Pooling data from 39 trials, the risk of neurologic adverse events (NAEs) was a relative 41% lower for ICI patients compared with comparator groups taking other drug regim...

Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency
https://www.medpagetoday.com/hematologyoncology/prostatecancer/98370

Apr 22nd, 2022 - A group of prostate cancer specialists, joined by MedPage Today contributor and prostate cancer patient Howard Wolinsky, made a case to stop referring to low-grade prostate cancer (Gleason ≤6) as cancer. (Journal of Clinical Oncology) The International Association for the Study of Lung Cancer issued a statement in support of efforts to reduce harmful environmental emissions, improve air quality...

FDA Panel Puts PI3K Inhibitors for Blood Cancers on Notice
https://www.medpagetoday.com/hematologyoncology/hematology/98365

Apr 22nd, 2022 - Future FDA approvals of four existing PI3K inhibitors for hematologic malignancies should have supporting survival data from randomized clinical trials, according to an advisory committee. By a 16-0 vote, with one abstention, the Oncologic Drugs Advisory Committee (ODAC) decided that a pattern of worse overall survival (OS) with PI3K inhibitors in hematologic cancers warrants randomized control...

Medical Financial Hardship Linked With Worse Cancer Survival
https://www.medpagetoday.com/hematologyoncology/othercancers/98315

Apr 20th, 2022 - Financial hardship had a significant association with premature death among cancer survivors, irrespective of health insurance coverage, an analysis of 25,000 cancer survivors showed. Almost 30% of patients, ages 18-64, reported medical financial hardship, which was associated with a 17% excess mortality risk compared with same-age patients who did not report medical financial hardship, accordi...

PD-1 Inhibition Shows 'Clear' Benefit in Nasopharyngeal Carcinoma
https://www.medpagetoday.com/hematologyoncology/othercancers/98310

Apr 20th, 2022 - Adding the PD-1 inhibitor tislelizumab to chemotherapy led to a progression-free survival (PFS) improvement for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to updated results from a phase III randomized trial. Over a follow-up of 15.5 months, the median PFS was 9.6 months for patients randomized to tislelizumab plus gemcitabine-cisplatin chemotherapy compared...

Eligibility Criteria Exclude More Blacks From Pancreatic Cancer Trials
https://www.medpagetoday.com/hematologyoncology/othercancers/98283

Apr 19th, 2022 - Black patients were more likely to be excluded from pancreatic cancer clinical trials when traditional eligibility criteria were used, a cross-sectional study found. Among individuals who sought care at a single center for pancreatic ductal adenocarcinoma (PDAC) from 2010 to 2019, traditional criteria led to more Black patients being ineligible for clinical trial participation compared with whi...

Consolidation Intensification Fails in High-Risk Metastatic Ewing Sarcoma
https://www.medpagetoday.com/hematologyoncology/othercancers/98266

Apr 18th, 2022 - Adding high-dose treosulfan and melphalan as further consolidation therapy for high-risk metastatic Ewing sarcoma failed to improve survival outcomes, a randomized phase III study showed. In an intention-to-treat population of 109 patients receiving standard induction and consolidation therapy, no significant difference was seen in event-free survival (EFS) between a group that also received hi...

Gene Score, Endocrine Response Can Guide Early Breast Cancer Therapy
https://www.medpagetoday.com/hematologyoncology/breastcancer/98244

Apr 17th, 2022 - Use of the 21-gene recurrence score (RS) combined with response to 3-week preoperative endocrine therapy can be used to guide systemic therapy in early breast cancer patients with limited nodal involvement, and can help avoid overtreatment with chemotherapy, according to German investigators. Among patients with early, hormone receptor (HR)-positive/HER2-negative breast cancer, the 5-year invas...

Blood Type and Clot Risk; Clue to Immunotherapy Action in Men; CAR-T Viral Payload
https://www.medpagetoday.com/hematologyoncology/othercancers/98245

Apr 15th, 2022 - Cancer patients with blood types A, B, and AB appear to have a greater risk of cancer-related blood clots as compared with patients who have type O. (Blood Advances) Male sex hormones' interaction with T cells may explain why women respond better to cancer immunotherapy for tumors unrelated to reproductive organs. (Ohio State University, Science Immunology) In a study involving preclinical mode...

BTK Inhibitor Shows Potential in Immune Thrombocytopenia
https://www.medpagetoday.com/hematologyoncology/hematology/98188

Apr 13th, 2022 - An investigational oral Bruton's tyrosine kinase (BTK) inhibitor was tolerable and yielded rapid and durable responses in pretreated patients with immune thrombocytopenia (ITP), according to results of an open-label phase I/II trial. In the 60-patient study, 40% (95% CI 28-53) had a platelet response to rilzabrutinib at a median 167.5 days of treatment, reported David Kuter, MD, of Massachusett...

RT Prior to Mastectomy, Reconstruction Shows Promise
https://www.medpagetoday.com/hematologyoncology/breastcancer/98136

Apr 8th, 2022 - Radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DIEP) flap reconstruction is feasible and safe, with low rates of postoperative complications and good aesthetic results, results of the PRADA study suggested. In the prospective multicenter trial of 33 patients, just four (12%) had an open breast wound of greater than 1 cm requiring dressing or packing (t...

Mind-Body Link in Cancer Outcomes; NCI Director Steps Down; Breast Cancer and CVD
https://www.medpagetoday.com/hematologyoncology/othercancers/98127

Apr 8th, 2022 - Good psychological health contributes to better clinical outcomes in cancer patients, but what specific factors have the biggest impact? (Journal of Clinical Oncology) Updated guidance from the FDA encourages hospitals and endoscopy centers to complete the transition to "innovative duodenoscope designs," including disposable components and fully disposable duodenoscopes. National Cancer Institu...

Study Confirms Declining Mammography Rates in Breast Cancer Survivors
https://www.medpagetoday.com/hematologyoncology/breastcancer/98112

Apr 7th, 2022 - Rates of follow-up mammography among breast cancer survivors declined significantly during the last decade, particularly among younger women, an analysis of health claims data showed. Rates of annual mammography decreased from 74.1% in 2004 to 67.1% in 2016, with all of the decline occurring from 2009 to 2016. Among breast cancer survivors ages 40 to 49, mammography rates decreased by 2.8% a ye...

Study Confirms Favorable Prognosis for HPV-Positive Cervical Cancer
https://www.medpagetoday.com/hematologyoncology/cervicalcancer/98085

Apr 6th, 2022 - Tumor RNA sequencing for high-risk (hr)HPV infection showed that almost half of women with HPV-negative cervical cancer had the more favorable HPV-positive disease, a large Swedish study showed. Deep sequencing with PCR technology showed that 169 of 392 cervical cancers initially identified as HPV-negative were actually hrHPV positive. Women with hrHPV-positive cancers had a 43% lower excess mo...